Translating Pre-Clinical Research to Clinical Patient Care™

JMSACL Logo

Associate Editors : JMSACL


Anne Bendt, PhD
Singapore Lipidomics Incubator (SLING), National University of Singapore, Singapore

Lipidomics

Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Associate Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization.

Melissa Budelier, PhD
TriCore Reference Laboratories

Toxicology
TDM
Clinical Implementation
Method Development & Validation
Proteomics
Small Molecules
Biomarkers
Diagnostics

Dr. Budelier the Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification.

Christopher Chouinard, PhD
Clemson University, Melbourne, Florida, United States

Instrumentation
Steroids
Ion Mobility

I received my PhD from University of Florida in 2016, where I developed ion mobility-mass spectrometry (IM-MS) methods for steroids and vitamin D metabolites. I then worked as post-doctoral research at Pacific Northwest National Laboratory, building Structures for Loss Ion Manipulations (SLIM) ion mobility instrumentation for application in metabolomics and proteomics. Since 2018, I have been an Assistant Professor at Florida Institute of Technology. Work in my research group focuses on structurally selective reactions for improved characterization of steroids and other controlled substances with IM-MS.

Robert Gurke, PhD
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

Lipidomics
Metabolomics
Biomarkers
Clinical Implementation
Method Development & Validation

Robert Gurke received his diploma in chemistry at the Humboldt-University zu Berlin, Germany in 2012 followed by his doctoral thesis at the Technische Universität Dresden in 2016. After a short period as study director in a GLP-compliant bioanalytical company in Berlin he started working as research associate at the Institute of Clinical Pharmacology in Frankfurt under the guidance of Prof. Geisslinger. Mr Gurke is performing LC-MS/MS analysis since starting his doctoral thesis and gained broad experience in the field of developing and validating methods for the determination of exogenous and endogenous small molecules in different complex matrices.

Liam Heaney, PhD
Loughborough University, Loughborough, United Kingdom

Small Molecules
Toxicology
Quantitative MS
Biomarkers
Metabolomics
Breath Analysis
Anti-Doping

Dr Liam Heaney is a Senior Lecturer in Bioanalytical Science based in the School of Sport, Exercise and Health Sciences at Loughborough University, UK. His research interests focus principally on the use of high-throughput measurement of small molecule biomarkers, with aligned interests in discovery-based omics applications. These activities include projects that span across multiple disciplines including clinical diagnostic and prognostic applications, nutrition and physiology, and sports anti-doping/drugs of abuse. His work is centered around the application of analytical chemistry applying both gas chromatography and liquid chromatography-mass spectrometry. He sits as an Executive Committee Member of the British Mass Spectrometry Society and was recently voted onto The Analytical Scientists Top 40 Under 40 for his work in promoting the use of mass spectrometry in sport & exercise science/nutrition.

Daniel Holmes, MD, FRCPC
St. Paul’s Hospital, Vancouver, British Columbia, Canada

Endocrinology
Data Science
Small Molecules
Automation
Sample Prep

Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine.

Randall Julian, PhD
Indigo BioAutomation, Carmel, Indiana, United States
Data Science
Machine Learning

Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to analyze data from laboratories across the US automatically. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue.

Mark Kushnir, PhD
ARUP Institute for Clinical & Experimental Pathology, Salt Lake City, Utah, United States

Endocrinology
Proteomics
Small Molecules
Biomarkers
Method Development & Validation
Sample Prep
Quantitative MS
Clinical Implementation

Mark Kushnir is Scientific Director, Mass Spectrometry R&D at ARUP Institute for Clinical and Experimental Pathology and Adjunct Assistant Professor at the Department of Pathology, University of Utah School of Medicine. He received PhD in Analytical Chemistry from Uppsala University (Uppsala, Sweden); his main areas of interest include development, application and clinical evaluation of novel mass spectrometry based clinical diagnostic methods for small molecule, protein and peptide biomarkers. He is author/coauthor of over 100 scientific peer reviewed publications.

Ruben Y. Luo, PhD, DABCC
Stanford University

Glycomics
Instrumentation
Metabolomics
New Technologies
Proteomics
Protein Variant Detection
Sample Prep
Separations

Ruben Y. Luo, PhD, DABCC, FADLM is an Assistant Professor of Pathology at Stanford University and Associate Director of Clinical Chemistry Laboratory at Stanford Health Care. He has been dedicated to innovations in translational laboratory medicine: discovery of novel diagnostic markers and innovation of diagnostic technologies. His research focuses on (1) discovering the clinical diagnostic value of molecular characteristics of protein biomarkers, and (2) developing high-resolution mass spectrometry and label-free optical sensing technologies for characterization and accurate measurement of biomarkers. He completed his clinical chemistry fellowship at University of California San Francisco. Prior to the fellowship, he had several years of work experience in the clinical diagnostic industry. He received his PhD in analytical chemistry from Stanford University, and BS in chemistry from Peking University.

Grace van der Gugten, B.Sc. Chemistry
Alberta Precision Laboratories

Small Molecules
Clinical Implementation

Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Lab Scientist in the Newborn Screening and Biochemical Genetics lab at Alberta Precision Laboratories in Edmonton. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!).

Elizabeth Want, PhD
Imperial College London, London, United Kingdom
Metabolomics
Toxicology

Liz is the Waters Senior Lecturer in Molecular Spectroscopy in the Department of Surgery and Cancer. She joined Imperial College in 2006 after working as a postdoctoral researcher at the Scripps Research Institute in La Jolla, CA. At Imperial College, she was initially a postdoctoral researcher for the Consortium for Metabonomic Toxicology (COMET) group. Her research focuses primarily on the development and application of novel MS-based techniques for metabolic phenotyping and on the fusion of MS methods with chemometric analysis, which is currently a significant bottleneck in the analysis pipeline. Broadly, her research at Imperial College has involved the development, optimisation and application of UPLC-MS methodologies for the analysis of biological samples, largely in the context of metabolic phenotyping: serum, urine, tissue, amniotic fluid, and microdialysates. Liz is applying these methods to biomedical research areas including toxicology, cardiovascular disease, neonatal disease and development, maternal exposures and effects on early childhood, and neurological diseases.